JP Morgan Chase
RVMD icon

JP Morgan Chase’s Revolution Medicines RVMD Stock Holding History

JP Morgan Chase’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$637M Buy
3,298,066
+2,996,673
+994% +$438M 0.04% 392
2026
Q1 		$27.9M Sell
301,393
-120,234
-29% -$12.1M ﹤0.01% 1801
2025
Q4 		$33.6M Sell
421,627
-2,076,700
-83% -$136M ﹤0.01% 1635
2025
Q3 		$117M Sell
2,498,327
-338,901
-12% -$13.3M 0.01% 916
2025
Q2 		$104M Sell
2,837,228
-865,681
-23% -$33.3M 0.01% 915
2025
Q1 		$131M Sell
3,702,909
-126,440
-3% -$5.13M 0.01% 816
2024
Q4 		$167M Sell
3,829,349
-308,571
-7% -$15.6M 0.01% 723
2024
Q3 		$188M Buy
4,137,920
+1,022,345
+33% +$44.5M 0.01% 708
2024
Q2 		$121M Sell
3,115,575
-393,529
-11% -$14.7M 0.01% 833
2024
Q1 		$113M Sell
3,509,104
-882,525
-20% -$26.2M 0.01% 886
2023
Q4 		$126M Buy
4,391,629
+111,710
+3% +$2.68M 0.01% 785
2023
Q3 		$118M Buy
4,279,919
+312,166
+8% +$9.26M 0.01% 746
2023
Q2 		$106M Buy
3,967,753
+705,115
+22% +$17.3M 0.01% 797
2023
Q1 		$70.7M Buy
3,262,638
+666,584
+26% +$16.4M 0.01% 942
2022
Q4 		$61.8M Buy
2,596,054
+804,606
+45% +$17.1M 0.01% 1005
2022
Q3 		$35.3M Sell
1,791,448
-61,404
-3% -$1.35M 0.01% 1221
2022
Q2 		$36.1M Buy
1,852,852
+512,237
+38% +$9.97M 0.01% 1213
2022
Q1 		$34.2M Buy
1,340,615
+58,914
+5% +$1.28M ﹤0.01% 1384
2021
Q4 		$32.3M Sell
1,281,701
-36,943
-3% -$1.04M ﹤0.01% 1452
2021
Q3 		$36.3M Sell
1,318,644
-66,891
-5% -$1.95M ﹤0.01% 1351
2021
Q2 		$44M Buy
1,385,535
+149,364
+12% +$5.21M 0.01% 1278
2021
Q1 		$56.7M Buy
1,236,171
+76,031
+7% +$3.41M 0.01% 1104
2020
Q4 		$45.9M Buy
1,160,140
+49,137
+4% +$1.94M 0.01% 1120
2020
Q3 		$37.7M Buy
1,111,003
+337,784
+44% +$9.36M 0.01% 1120
2020
Q2 		$24.4M Buy
773,219
+260,088
+51% +$8.18M ﹤0.01% 1247
2020
Q1 		$11.2M Buy
+513,131
New +$14.2M ﹤0.01% 1648

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

JP Morgan Chase's RVMD Position: Q2 2026 in Review

JP Morgan Chase increased its Revolution Medicines (RVMD) stake by 994% in Q2 2026, buying an estimated $438M and bringing the position to 3,298,066 shares worth $637M. The position accounts for 0.04% of the portfolio, ranked #392.

JP Morgan Chase first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. 689 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • JP Morgan Chase held 3,298,066 shares of Revolution Medicines worth $637M as of Q2 2026.
  • JP Morgan Chase bought 2,996,673 Revolution Medicines shares in Q2 2026, an estimated $438M.
  • Revolution Medicines made up 0.04% of JP Morgan Chase's portfolio in Q2 2026, its #392 holding.
  • JP Morgan Chase first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • 689 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.